


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(Original)** A compound of formula (I):



wherein R^1 represents aliphatic hydrocarbon optionally having substituent(s),
ring A represents a cyclic group comprising at least one nitrogen atom optionally having further substituent(s) besides R^1 ,
ring B represents a cyclic group optionally having substituent(s) and is attached to ring A via a bond,
G represents a bond or a spacer comprising 1-4 atoms in the main chain,
J represents a spacer having a hydrogen-bond accepting group optionally having substituent(s),
K represents a bond or a spacer comprising 1-4 atoms in the main chain, and
ring D represents a cyclic group optionally having substituent(s), which may form a ring together with a substituent on J,
a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

2. **(Original)** The compound according to claim 1, wherein the hydrogen-bond accepting group in J is carbonyl, thiocarbonyl, imino, sulfonyl or sulfinyl, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

3. **(Original)** The compound according to claim 1,
wherein J is -CO-, -CONR²-, -NR²CO-, -OCO-, -COO-, -CS-, -CSNR²-, -NR²CS-, -O-CS-, -CS-O-, -SO₂-, -SO₂NR²-, -NR²SO₂-, -O-SO₂-, -SO₂-O-, -S(O)-, -S(O)NR²-, -NR²S(O)-, -O-S(O)-, -S(O)-O-, or -C(=NR³)-,
wherein R² represents a hydrogen atom, optionally substituted aliphatic hydrocarbon or an optionally substituted cyclic group and R³ represents a hydrogen atom, cyano, optionally

protected hydroxy, optionally substituted amino, optionally substituted aliphatic hydrocarbon or an optionally substituted cyclic group,

a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

4. **(Original)** The compound according to claim 1,

wherein J is -N(COR⁴)-, -N(CONHR⁵)-, -N(COOR⁶)-, or -N(SO₂R⁷)-,

wherein R⁴, R⁵, R⁶ and R⁷ each represents a hydrogen atom, optionally substituted aliphatic hydrocarbon or an optionally substituted cyclic group,

a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

5. **(Original)** The compound according to claim 1, wherein the cyclic group

represented by ring D is a C3-15 mono-, bi- or tri-cyclic aromatic carbocyclic ring which may be partially or completely saturated, or a 3-15 membered mono-, bi- or tri-cyclic aromatic heterocyclic ring comprising 1-5 of heteroatom selected from oxygen, nitrogen and sulfur which may be partially or completely saturated,


a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

6. **(Original)** The compound according to claim 1, wherein the cyclic group


represented by ring D is a C3-15 mono-, bi- or tri-cyclic aromatic carbocyclic ring, or a 3-15 membered mono-, bi- or tri-cyclic aromatic heterocyclic ring containing 1-5 of heteroatom,

a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

7. **(Original)** The compound according to claim 1, wherein



wherein all symbols have the same meanings as in claim 1,




wherein N is a cyclic ring comprising at least one nitrogen atom and

optionally having substituent(s) and R¹ has the same meaning as in claim 1,


a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

8. **(Original)** The compound according to claim 7,



wherein all symbols have the same meanings as in claim 1,
is piperidine, piperazine, pyrrolidine, 1,4-diazepane, 1,2,3,6-tetrahydropyridine or 8-azabicyclo[3.2.1]octane ring optionally having substituent(s),
a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

9. **(Currently Amended)** A pharmaceutical composition comprising a compound of formula (I)



wherein R^1 represents aliphatic hydrocarbon optionally having substituent(s),
ring A represents a cyclic group comprising at least one nitrogen atom optionally having further substituent(s) besides R^1 ,
ring B represents a cyclic group optionally having substituent(s) and is attached to ring A via a bond,
G represents a bond or a spacer comprising 1-4 atoms in the main chain,
J represents a spacer having a hydrogen-bond accepting group optionally having substituent(s),
K represents a bond or a spacer comprising 1-4 atoms in the main chain, and
ring D represents a cyclic group optionally having substituent(s), which may form a ring together with a substituent on J,
a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and
a pharmaceutically acceptable carrier or diluent.

10. **(Original)** The composition according to claim 9, which is a chemokine receptor antagonist.

11. **(Original)** The composition according to claim 10, wherein the chemokine receptor is CCR1.

12. **(Original)** The composition according to claim 10, wherein the chemokine receptor is CCR5.

13. **(Original)** The composition according to claim 10, which is a medicament for the prevention and/or treatment of human immunodeficiency virus infectious disease, acquired immunodeficiency syndrome and/or organ rejection in transplantation.

14. **(Original)** The composition according to claim 10, which is a medicament for the prevention and/or treatment of multiple sclerosis and/or arthritis.

15. **(Original)** A method for the prevention and/or treatment of diseases induced by a chemokine receptor in a mammal, which comprises administering to an mammal an effective amount of the compound according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof.

16. **(Cancelled)**

17. **(Original)** A medicament comprising the compound according to claim 1, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and one or more selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, a fusion inhibitor, an HIV integrase inhibitor, a chemokine inhibitor, a steroidal drug, interferon, an immunosuppressant, an aldose reductase inhibitor, a cannabinoid-2 receptor agonist, adrenocorticotrophic hormone, a metalloproteinase inhibitor, a non-steroidal anti-inflammatory drug, a prostaglandin drug, a phosphodiesterase inhibitor, a disease modifying anti-rheumatic drug, an anti-inflammatory enzyme drug, a cartilage-protecting drug, a T-cell inhibitor, a TNF- α inhibitor, an IL-6 inhibitor, an interferon γ agonist, an IL-1 inhibitor and an NF- κ B inhibitor.